KR20120100886A - 자가포식의 효능 있는 소분자 억제제 및 이의 사용 방법 - Google Patents

자가포식의 효능 있는 소분자 억제제 및 이의 사용 방법 Download PDF

Info

Publication number
KR20120100886A
KR20120100886A KR1020127004431A KR20127004431A KR20120100886A KR 20120100886 A KR20120100886 A KR 20120100886A KR 1020127004431 A KR1020127004431 A KR 1020127004431A KR 20127004431 A KR20127004431 A KR 20127004431A KR 20120100886 A KR20120100886 A KR 20120100886A
Authority
KR
South Korea
Prior art keywords
compound
autophagy
lower alkyl
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127004431A
Other languages
English (en)
Korean (ko)
Inventor
준잉 유안
다웨이 마
준리 리우
리홍 창
Original Assignee
상하이 인스티튜트 오브 오가닉 케미스트리, 차이니즈 아카데미 오브 사이언시스
프레지던트 앤드 펠로우즈 오브 하바드 칼리지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42829077&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20120100886(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 상하이 인스티튜트 오브 오가닉 케미스트리, 차이니즈 아카데미 오브 사이언시스, 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 filed Critical 상하이 인스티튜트 오브 오가닉 케미스트리, 차이니즈 아카데미 오브 사이언시스
Publication of KR20120100886A publication Critical patent/KR20120100886A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020127004431A 2009-07-21 2010-07-21 자가포식의 효능 있는 소분자 억제제 및 이의 사용 방법 Withdrawn KR20120100886A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22716409P 2009-07-21 2009-07-21
US61/227,164 2009-07-21
US29673510P 2010-01-20 2010-01-20
US61/296,735 2010-01-20

Publications (1)

Publication Number Publication Date
KR20120100886A true KR20120100886A (ko) 2012-09-12

Family

ID=42829077

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127004431A Withdrawn KR20120100886A (ko) 2009-07-21 2010-07-21 자가포식의 효능 있는 소분자 억제제 및 이의 사용 방법

Country Status (18)

Country Link
US (1) US20120258975A1 (enExample)
EP (1) EP2456761A2 (enExample)
JP (1) JP2013500255A (enExample)
KR (1) KR20120100886A (enExample)
CN (1) CN102574816A (enExample)
AU (1) AU2010276223A1 (enExample)
BR (1) BR112012001316A2 (enExample)
CA (1) CA2767772A1 (enExample)
CL (1) CL2012000163A1 (enExample)
IL (1) IL217502A0 (enExample)
IN (1) IN2012DN01478A (enExample)
MX (1) MX2012000940A (enExample)
PE (1) PE20120798A1 (enExample)
PH (1) PH12012500097A1 (enExample)
RU (1) RU2012105914A (enExample)
SG (1) SG177486A1 (enExample)
WO (1) WO2011011522A2 (enExample)
ZA (1) ZA201201224B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504586A (ja) 2009-09-10 2013-02-07 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 脱ユビキチン化酵素およびユビキチン化ポリペプチドを調節するための方法および材料
US8598344B2 (en) * 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
EA023998B1 (ru) 2011-03-04 2016-08-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Аминохинолины в качестве ингибиторов киназ
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
EA027531B1 (ru) * 2011-09-13 2017-08-31 Игорь Ронинсон ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-κB
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
JP2016504365A (ja) * 2012-12-28 2016-02-12 アメリカ合衆国 Ｕｓｐ１／ｕａｆ１デユビキチナーゼ複合体阻害剤及びその使用
ES2790675T3 (es) 2013-02-01 2020-10-28 Wellstat Therapeutics Corp Compuestos de amina que tienen actividad anti-inflamatoria, antifúngica, antiparasitaria y anticáncer
TWI630203B (zh) 2013-02-21 2018-07-21 葛蘭素史克智慧財產發展有限公司 做為激酶抑制劑的喹唑啉類
EP2961409A1 (en) * 2013-02-26 2016-01-06 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
WO2014145512A2 (en) * 2013-03-15 2014-09-18 President And Fellows Of Harvard College Potent small molecule inhibitors of autophagy, and methods of use thereof
JP2016517439A (ja) * 2013-03-15 2016-06-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 医学的状態の治療のためのクロマチン修飾因子の標的化
US9393244B2 (en) 2013-03-15 2016-07-19 Georgetown University Increasing parkin activity by administering a deubiquitinating enzyme inhibitor
US11306328B2 (en) * 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
CN104164471A (zh) * 2013-11-04 2014-11-26 复旦大学 基于细胞自噬的抗肿瘤药物的筛选方法
WO2016182812A1 (en) * 2015-05-08 2016-11-17 The Board Of Regents Of The University Of Texas System Activation of neuronal store-operated calcium entry pathway for the treatment of alzheimer's disease
BR112018006873A2 (pt) * 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
EP3184514A1 (en) * 2015-12-23 2017-06-28 Deutsches Krebsforschungszentrum Autophagy inhibitors
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
CN108929373A (zh) * 2017-05-22 2018-12-04 苏州偶领生物医药有限公司 一种共价键修饰哺乳动物atg8 同源物的方法
WO2020021064A1 (en) 2018-07-26 2020-01-30 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
CN109721554A (zh) * 2019-01-08 2019-05-07 贵州大学 一类4-氨基喹唑啉类化合物及其制备方法和应用
HUE065486T2 (hu) 2019-05-10 2024-05-28 Deciphera Pharmaceuticals Llc Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai
PE20220592A1 (es) 2019-05-10 2022-04-22 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos
CA3143489A1 (en) 2019-06-17 2020-12-24 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
US20210215710A1 (en) * 2019-12-23 2021-07-15 University Health Network Methods for use of cdx2 as a biomarker to guide use of autophagy inhibitors in ovarian cancer
EP4114946A1 (en) 2020-03-04 2023-01-11 Regeneron Pharmaceuticals, Inc. Methods and compositions for sensitization of tumor cells to immune therapy
CN112608302B (zh) * 2020-12-28 2022-05-24 郑州大学第一附属医院 低氧还原激活靶向泛素化降解egfr蛋白的喹唑啉类衍生物及其应用
US20240092800A1 (en) * 2021-01-14 2024-03-21 Georgetown University Usp13 inhibitors and methods of use thereof
WO2022187411A1 (en) * 2021-03-02 2022-09-09 Kumquat Biosciences Inc. Heterocycles and uses thereof
EP4395549A1 (en) 2021-09-01 2024-07-10 Oerth Bio LLC Compositions and methods for targeted degradation of proteins in a plant cell
CN114224895B (zh) * 2022-01-06 2023-06-30 山东农业大学 3-甲基腺嘌呤在清除牛乳腺上皮细胞内无乳链球菌中的应用
JP2025515285A (ja) 2022-04-20 2025-05-14 カムクワット バイオサイエンシーズ インコーポレイテッド 大環状複素環及びその使用
CN116179494B (zh) * 2022-10-13 2024-01-26 武汉生物制品研究所有限责任公司 低成瘤性的mdck细胞株及其构建方法和应用
DE102022131212A1 (de) 2022-11-25 2024-05-29 Dr. Ing. H.C. F. Porsche Aktiengesellschaft Luftzufuhrvorrichtung einer Kraftfahrzeugkarosserie eines Kraftfahrzeugs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS542327A (en) * 1977-06-07 1979-01-09 Sankyo Co Ltd Agricultural and horticultural pesticide
JPS542325A (en) * 1977-06-07 1979-01-09 Sankyo Co Ltd Agricultural and horticultural pesticide
GT198900008A (es) * 1988-01-29 1990-07-17 Derivados de quinolina, quinazolina y cinolina.
IL89027A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
US5034393A (en) * 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
US5227387A (en) * 1991-09-03 1993-07-13 Dowelanco Quinoline nematicidal method
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6262059B1 (en) * 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
DE10042060A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1481971B1 (en) * 2002-02-06 2011-11-16 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
JP2004059454A (ja) * 2002-07-25 2004-02-26 Japan Energy Corp キナゾリン誘導体及びＮＦ−κＢ活性化阻害剤
JP4934432B2 (ja) * 2004-02-19 2012-05-16 レクサン ファーマシューティカルズ インコーポレイテッド キナゾリン誘導体およびキナゾリン誘導体の治療への使用
JP2008526734A (ja) * 2004-12-31 2008-07-24 エスケー ケミカルズ カンパニー リミテッド 糖尿及び肥満治療予防に有効なキナゾリン誘導体
EP1856247B1 (en) 2005-01-19 2016-05-04 The Trustees of The University of Pennsylvania Regulation of autophagy and cell survival
WO2008122038A1 (en) * 2007-04-02 2008-10-09 President And Fellows Of Harvard College Regulating autophagy
US8039502B2 (en) 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens

Also Published As

Publication number Publication date
EP2456761A2 (en) 2012-05-30
US20120258975A1 (en) 2012-10-11
AU2010276223A1 (en) 2012-03-08
WO2011011522A2 (en) 2011-01-27
RU2012105914A (ru) 2013-08-27
CL2012000163A1 (es) 2012-07-13
PH12012500097A1 (en) 2011-01-27
ZA201201224B (en) 2012-10-31
JP2013500255A (ja) 2013-01-07
IL217502A0 (en) 2012-02-29
IN2012DN01478A (enExample) 2015-06-05
BR112012001316A2 (pt) 2017-08-08
CN102574816A (zh) 2012-07-11
WO2011011522A3 (en) 2011-08-25
SG177486A1 (en) 2012-02-28
MX2012000940A (es) 2012-05-08
PE20120798A1 (es) 2012-07-27
CA2767772A1 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
KR20120100886A (ko) 자가포식의 효능 있는 소분자 억제제 및 이의 사용 방법
JP2013500255A5 (enExample)
JP6790040B2 (ja) Ｆａｓｎを阻害するための新規化合物および組成物
JP5403709B2 (ja) 新規なトリサイクリック誘導体またはその薬学的に許容可能な塩、それらの製造方法およびそれらを含む薬学的組成物
CA2736097C (en) Carbazole compounds for inhibition of nf-kb activity
CN109790169A (zh) 具有作为usp30抑制剂活性的氰基吡咯烷衍生物
JP2010501593A (ja) イソキノリン、キナゾリンおよびフタラジン誘導体
TW201245161A (en) 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
US20140364431A1 (en) Quinoline and cinnoline derivatives and their applications
SK12332002A3 (sk) Deriváty chinolínu ako alfa 2 antagonisty
WO2012079079A1 (en) Production of induced pluripotent stem cells
AU2020256301A1 (en) Fused bicyclic compounds for the treatment of disease
CN106946760A (zh) 靛玉红衍生物或药学上能接受的盐用于抗肿瘤药物及制备方法
WO2014021337A1 (ja) 精神神経疾患又は悪性腫瘍に関する化合物及び医薬組成物
EP2397471A1 (en) Benzimidazole compounds and their use
US8501957B2 (en) Benzimidazole compounds and their use as anticancer agents
EP3440070B1 (en) Mdr-reversing 8-hydroxy-quinoline derivatives
CN101341151A (zh) 二氮杂䓬酮类
CN103044460A (zh) 3,5,7-三苯基-5H-噻唑并[3,2-a]嘧啶类衍生物及应用
KR102578288B1 (ko) 피라졸로피리다진 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
US20220396575A1 (en) Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient
US6593324B2 (en) Dervatives of quinoline as alpha-2 antagonists
CN107501283B (zh) 取代芳甲杂基取代苯胺基缩乙二醇醚环代喹唑啉的制备及肿瘤治疗药物应用
AU2020244861A1 (en) Quinoline derivatives and their use for the treatment of cancer
EP1433789A1 (en) Pyrrolopyrazines and their use as selective apoptosis inducers

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120220

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid